An interventional study of New generation eHF and Commercial eHF in Cow Milk Protein Allergy, sponsored by Société des Produits Nestlé (SPN). Not yet recruiting. Open to participants aged 29 Days to 22 Weeks. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by Société des Produits Nestlé (SPN) (part of Nestlé S.A.) · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Growth and safety Outcomes in infants with CMPA fed a novel extensively hydrolyzed formula.
Société des Produits Nestlé (SPN) is the lead sponsor of 324 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
New generation eHF
Dietary Supplement: New generation eHF
Commercial eHF
Dietary Supplement: Commercial eHF
New generation of a whey-based eHF formula intended for the dietary management of infants with CMPA.
Commercial whey-based eHF formula intended for the dietary management of infants with CMPA.
Weight Gain Over 16 Weeks
To demonstrate non-inferiority in growth in infants fed with the Test formula, compared to infants fed with the Control formula over the first 16 weeks of formula intake.
Time frame: 16 weeks
Incidence of Adverse Events of Special Interest (AESIs)
To evaluate the safety and tolerability of the Test formula, including effects on "adverse events of special interest (AESIs)", which include lower respiratory tract infections (LRTIs), upper respiratory tract infections (URTIs), ear infections/otitis media, gastrointestinal infections and other viral or bacterial infections including urinary tract infections (UTIs).
Time frame: 52 weeks
Growth Parameters: Weight
The growth by body weight (in g) of infants over 52 weeks.
Time frame: 52 weeks
Growth Parameters: Length
The growth by body length (in cm) of infants over 52 weeks
Time frame: 52 weeks
Quality of Life Scores (ITQOL)
Quality of life over 52-weeks assessed by validated Quality of Life (QoL) scale: Infant and Toddler Quality of Life \[ITQOL\] Minimum score: 0 Maximum score: 100 Interpretation: Higher scores indicate better health-related quality of life, better functioning, or less negative impact on the child/family (depending on the specific domain). A score of 0 represents the worst health/status, while 100 represents the best health/status
Time frame: 52 weeks
Stool Frequency and Stool Characteristics (BITSS)
Stool frequency and characteristics over 52 weeks based on Brussels Infant and Toddler Stool Scale (BITSS). Scale categories: 7 stool photographs corresponding to stool consistency types BITSS photographs are often grouped into: Hard: Types 1-3 Formed: Type 4 Loose: Types 5-6 Watery: Type 7 Interpretation: Lower categories (1-3): harder stools, potentially associated with constipation. Middle category (4): formed/normal stool consistency. Higher categories (5-7): increasingly loose to watery stools, potentially associated with diarrhea.
Time frame: 52 weeks
Resolution of CMPA-Related Symptoms
Rate of adequate clinical response and time to symptom resolution of CMPA-related symptoms (in days) collected on patient-reported outcome tool (PRO) based on parent(s)/legally authorized representative(s) (LAR) report.
Time frame: 52 weeks
Formula intake compliance
Formula intake (in ml) compliance (number of feeds per day) based on parent(s)/LAR report records collected via electronic data capture (EDC)/interactive response technology (IRT).
Time frame: 52 weeks
Healthcare resources utilization
Healthcare Resources Utilization (HCRU) over the 52-week intervention period, based on parent(s)/LAR report and medical records (such as: number of hospitalizations, number of unscheduled emergency department attendances, general practitioner/pediatrician visits)
Time frame: 52 weeks
Growth Parameters: Head Circumference
The growth by head circumference (in cm) of infants over 52 weeks
Time frame: 52 weeks
Quality of Life Scores (FLIP)
Quality of life over 52-weeks assessed by validated QoL scale: Food hypersensitivity family Impact \[FLIP\] Lower categories (1-3): harder stools, potentially associated with constipation. Middle category (4): formed/normal stool consistency. Higher categories (5-7): increasingly loose to watery stools, potentially associated with diarrhea.
Time frame: 52 weeks
Resolution of Cow Milk Protein Allergy (CMPA)-Related Symptoms
Rate of adequate clinical response and time to symptom resolution of CMPA-related symptoms (in days) collected on Scoring Atopic Dermatitis Eczema Score (SCORAD) Minimum score: 0 Maximum score: 103 Interpretation: Higher scores indicate more severe eczema and therefore a worse outcome. Lower scores indicate less severe disease and a better outcome
Time frame: 52 weeks
Resolution of CMPA-Related Symptoms
Rate of adequate clinical response and time to symptom resolution of CMPA-related symptoms (in days) collected on Infant Gastrointestinal Symptom Questionnaire (IGSQ) Minimum score: 13 Maximum score: 65 Interpretation: Higher scores indicate more gastrointestinal symptoms and poorer feeding tolerance (worse outcome). Lower scores indicate fewer GI symptoms and better tolerance.
Time frame: 52 weeks
Resolution of CMPA-Related Symptoms
Rate of adequate clinical response and time to symptom resolution of CMPA-related symptoms (in days) collected on Cow's Milk-Related Symptom Score (CoMiSS). Minimum score: 0 Maximum score: 33 Interpretation: Higher scores indicate more severe cow's milk-related symptoms and therefore a worse outcome. Lower scores indicate fewer symptoms and a better outcome.
Time frame: 52 weeks
No study locations are listed for this record.
Start is estimated for Jul 2026; primary completion for Jul 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Société des Produits Nestlé (SPN) →